Bruchelt G, Klose C, Lischka M, Brandes M, Handgretinger R, Brueckner R
J Clin Med. 2023; 12(13).
PMID: 37445504
PMC: 10342853.
DOI: 10.3390/jcm12134469.
Saimuang K, Suttisintong K, Kaewchangwat N, Thanayupong E, Wongngam Y, Charoenphun P
RSC Adv. 2022; 11(41):25199-25206.
PMID: 35478920
PMC: 9037022.
DOI: 10.1039/d1ra04054e.
Feng J, Cheng F, Leung A, Lee V, Yeung E, Ching Lam H
Pediatr Investig. 2020; 4(3):168-177.
PMID: 33150310
PMC: 7520103.
DOI: 10.1002/ped4.12216.
Zhang Y, Wang J
Acta Pharm Sin B. 2020; 10(1):79-90.
PMID: 31993308
PMC: 6977162.
DOI: 10.1016/j.apsb.2019.12.005.
Kayano D, Kinuya S
Nucl Med Mol Imaging. 2018; 52(4):254-265.
PMID: 30100938
PMC: 6066492.
DOI: 10.1007/s13139-018-0523-z.
Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1.
Yanik G, Parisi M, Naranjo A, Nadel H, Gelfand M, Park J
J Nucl Med. 2017; 59(3):502-508.
PMID: 28887399
PMC: 5868501.
DOI: 10.2967/jnumed.117.195883.
MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.
Dubois S, Mody R, Naranjo A, Van Ryn C, Russ D, Oldridge D
Pediatr Blood Cancer. 2017; 64(11).
PMID: 28383813
PMC: 5605392.
DOI: 10.1002/pbc.26545.
Semi-quantitative scoring of skeletal metastases by I-mIBG scintigraphy in high-risk neuroblastoma.
Gaze M
Eur J Nucl Med Mol Imaging. 2017; 44(8):1251-1253.
PMID: 28258443
DOI: 10.1007/s00259-017-3660-1.
Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group.
Temple W, Mendelsohn L, Kim G, Nekritz E, Gustafson W, Lin L
Eur J Nucl Med Mol Imaging. 2015; 43(3):474-481.
PMID: 26338179
PMC: 4733400.
DOI: 10.1007/s00259-015-3179-2.
Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG).
Zhou M, Doral M, Dubois S, Villablanca J, Yanik G, Matthay K
Eur J Cancer. 2015; 51(16):2465-72.
PMID: 26254811
PMC: 4607645.
DOI: 10.1016/j.ejca.2015.07.023.
Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma.
Dubois S, Groshen S, Park J, Haas-Kogan D, Yang X, Geier E
Clin Cancer Res. 2015; 21(12):2715-21.
PMID: 25695691
PMC: 4470833.
DOI: 10.1158/1078-0432.CCR-14-3240.
Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma.
Dubois S, Allen S, Bent M, Hilton J, Hollinger F, Hawkins R
Br J Cancer. 2015; 112(4):644-9.
PMID: 25602966
PMC: 4333502.
DOI: 10.1038/bjc.2015.12.
Nothing but NET: a review of norepinephrine transporter expression and efficacy of 131I-mIBG therapy.
Streby K, Shah N, Ranalli M, Kunkler A, Cripe T
Pediatr Blood Cancer. 2014; 62(1):5-11.
PMID: 25175627
PMC: 4237663.
DOI: 10.1002/pbc.25200.
Patient-specific dosimetry using pretherapy [¹²⁴I]m-iodobenzylguanidine ([¹²⁴I]mIBG) dynamic PET/CT imaging before [¹³¹I]mIBG targeted radionuclide therapy for neuroblastoma.
Huang S, Bolch W, Lee C, Van Brocklin H, Pampaloni M, Hawkins R
Mol Imaging Biol. 2014; 17(2):284-94.
PMID: 25145966
PMC: 4336853.
DOI: 10.1007/s11307-014-0783-7.
68Gallium- and 90Yttrium-/ 177Lutetium: "theranostic twins" for diagnosis and treatment of NETs.
Werner R, Bluemel C, Allen-Auerbach M, Higuchi T, Herrmann K
Ann Nucl Med. 2014; 29(1):1-7.
PMID: 25139472
PMC: 4306729.
DOI: 10.1007/s12149-014-0898-6.
Destabilization of MYC/MYCN by the mitochondrial inhibitors, metaiodobenzylguanidine, metformin and phenformin.
Wang S, Hsiao R, Limpar M, Lomahan S, Tran T, Maloney N
Int J Mol Med. 2013; 33(1):35-42.
PMID: 24190252
PMC: 3868499.
DOI: 10.3892/ijmm.2013.1545.
Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group.
Yanik G, Parisi M, Shulkin B, Naranjo A, Kreissman S, London W
J Nucl Med. 2013; 54(4):541-8.
PMID: 23440556
PMC: 5503147.
DOI: 10.2967/jnumed.112.112334.
Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group.
Dubois S, Geier E, Batra V, Yee S, Neuhaus J, Segal M
Int J Mol Imaging. 2012; 2012:250834.
PMID: 23050139
PMC: 3463166.
DOI: 10.1155/2012/250834.
Tumor dosimetry using [124I]m-iodobenzylguanidine microPET/CT for [131I]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model.
Seo Y, Gustafson W, Dannoon S, Nekritz E, Lee C, Murphy S
Mol Imaging Biol. 2012; 14(6):735-42.
PMID: 22382618
PMC: 3369020.
DOI: 10.1007/s11307-012-0552-4.
Neuroblastoma: issues in transplantation.
Grupp S, Asgharzadeh S, Yanik G
Biol Blood Marrow Transplant. 2012; 18(1 Suppl):S92-100.
PMID: 22226119
PMC: 3260463.
DOI: 10.1016/j.bbmt.2011.10.020.
